News stories about Perrigo (NYSE:PRGO) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Perrigo earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.2176554051957 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Perrigo (NYSE PRGO) traded up $0.65 during midday trading on Wednesday, reaching $88.58. 409,434 shares of the company’s stock were exchanged, compared to its average volume of 1,662,557. The company has a current ratio of 1.72, a quick ratio of 1.24 and a debt-to-equity ratio of 0.54. The firm has a market capitalization of $12,250.00, a price-to-earnings ratio of -9.67, a PEG ratio of 1.85 and a beta of 0.64. Perrigo has a one year low of $63.68 and a one year high of $91.73.
Perrigo (NYSE:PRGO) last posted its quarterly earnings data on Thursday, November 9th. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.28. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The company had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the business posted $1.65 earnings per share. Perrigo’s quarterly revenue was down 2.0% on a year-over-year basis. research analysts anticipate that Perrigo will post 4.88 EPS for the current year.
PRGO has been the topic of several research analyst reports. Oppenheimer initiated coverage on shares of Perrigo in a research note on Thursday, September 7th. They set an “outperform” rating and a $88.00 price target on the stock. CIBC initiated coverage on shares of Perrigo in a research note on Thursday, September 7th. They set an “outperform” rating and a $88.00 price target on the stock. BidaskClub upgraded shares of Perrigo from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 9th. Cantor Fitzgerald lifted their price objective on shares of Perrigo from $93.00 to $107.00 and gave the company an “overweight” rating in a research note on Tuesday, September 12th. Finally, Canaccord Genuity restated a “buy” rating and issued a $100.00 price objective (up from $88.00) on shares of Perrigo in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the stock. Perrigo currently has an average rating of “Hold” and a consensus price target of $92.13.
In other news, EVP John Wesolowski sold 388 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.20, for a total transaction of $33,833.60. Following the transaction, the executive vice president now directly owns 248 shares in the company, valued at $21,625.60. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 1,051 shares of company stock worth $89,810. Company insiders own 6.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.com-unik.info/2017/12/27/perrigo-prgo-receiving-somewhat-positive-media-coverage-accern-reports.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
What are top analysts saying about Perrigo? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Perrigo and related companies.